ESR2 and breast carcinoma: In cells expressing both receptor types, ERβ acts as a dominant repressor of ERα function; thus ERβ negatively modulates ERα-mediated transcriptional activity [50–52] and inhibits ERα-mediated breast cancer cell proliferation and tumor formation [51, 53, 54].